Antiinfecciosos de uso sistémico falsificados y subestándares en Perú

Carlos Huamaní-Pacsi; Roberto Torres Olivera

doi:10.17843/rpmesp.2026.432.15577

Authors

Carlos Huamaní-Pacsi Centro Nacional de Control de Calidad, Instituto Nacional de Salud, Lima, Perú https://orcid.org/0009-0004-1393-4205
Roberto Torres Olivera Centro Nacional de Control de Calidad, Instituto Nacional de Salud, Lima, Perú https://orcid.org/0000-0002-6469-609X

DOI:

https://doi.org/10.17843/rpmesp.2026.432.15577

Keywords:

Substandard Drugs, Counterfeit Drugs, Drug Resistance Bacterial, Pharmacovigilance, Peru

Abstract

Substandard and falsified (SF) systemic anti-infective (SAI) medications detected by the National Health Authority of Peru between 2015 and 2023 were quantified and characterized. An observational, descriptive, and retrospective design was applied, based on test reports issued by the National Quality Control Center on the quality of SAIs, complemented with national evidence of antimicrobial resistance (AMR). Of 9799 pharmaceutical products evaluated, 1247 (12.7%) were SF; of these, 189 (15.2%) corresponded to SF SAIs, with falsified ones predominating (11.0%). The main groups were β-lactams (27.5%), sulfonamides/trimethoprim (26.5%), and quinolones (12.7%). 59.8% had informal origin, mostly from Lima (72%). The circulation of SF SAI medications could promote selective pressure, the spread of AMR, and therapeutic failure.

Downloads

Download data is not yet available.

References

World Health Organization. Global Antimicrobial Resistance and Use Surveillance System (GLASS) [Internet]. Geneva: WHO; [citado 9 agosto 2025]. Disponible en: https://www.who.int/initiatives/glass.

Ye Z, Li M, Jing Y, Liu K, Wu Y, Peng Z. What Are the Drivers Triggering Antimicrobial Resistance Emergence and Spread? Outlook from a One Health Perspective. Antibiotics. 2025;14(6):543. doi: 10.3390/antibiotics14060543.

Holmes AH, Moore LSP, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, et al. Understanding the mechanisms and drivers of antimicrobial resistance. Lancet. 2016 Jan 9;387(10014):176‑87. doi: 10.1016/S0140-6736(15)00473-0.

O’Neill J. Tackling drug resistant infections globally: final report and recommendations. Review on Antimicrobial Resistance [Internet].

London: HM Government; 2016 May [citado 15 agosto 2025]. Disponible en: https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf.

Poudel AN, Zhu S, Cooper N, Little P, Tarrant C, Hickman M, et al. The economic burden of antibiotic resistance: A systematic review and meta-analysis. PLoS One. 2023;18(5):e0285170. doi: 10.1371/journal.pone.0285170.

World Health Organization. A study on the public health and socioeconomicimpact of substandard and falsified medical products. Geneva: WHO; 2017. 84 p. Disponible en: https://www.who.int/publications/i/item/9789241513432.

Cavany S, Nanyonga S, Hauk C, Lim C, Tarning J, Sartorius B, et al. The uncertain role of substandard and falsified medicines in the emergence and spread of antimicrobial resistance. Nat Commun. 2023;14(1):6153. doi: 10.1038/s41467-023-41542-w.

Republica del Perú. Decreto Supremo N.° 016‑2011‑SA, Aprueban Reglamento para el Registro, Control y Vigilancia Sanitaria de Productos Farmacéuticos. Diario Oficial El Peruano. Lima: Ministerio de Salud; 2011 jul 27. [citado 26 agosto 2025]. Disponible en: https://cdn.www.gob.pe/uploads/document/file/272181/243290_16_-_DS_N_C2_B0_016-2011-SA.pdf20190110-18386-a4eggt.pdf?v=1656602611.

World Health Organization. Anatomical Therapeutic Chemical (ATC) Classification. [citado 2026 Mar 26]. Disponible en: https://www.who.int/tools/atc-ddd-toolkit/atc-classification.

Rojas-Cortés R. Substandard, falsified and unregistered medicines in Latin America, 2017–2018. Rev Panam Salud Publica. 2020;44:1. doi: 10.26633/RPSP.2020.125.

Kelesidis T, Falagas ME. Substandard/Counterfeit Antimicrobial Drugs. Clin Microbiol Rev. 2015;28(2):443-64. doi: 10.1128/CMR.00072-4.

Pisani E, Nistor A-L, Hasnida A, Parmaksiz K, Xu J, Kok MO. Identifying market risk for substandard and falsified medicines: an analytic framework based on qualitative research in China, Indonesia, Turkey and Romania. Wellcome Open Res. 2019;4:70. doi: 10.12688/wellcomeopenres.15236.1.

Ozawa S, Evans DR, Bessias S, Haynie DG, Yemeke TT, Laing SK, et al. Prevalence and Estimated Economic Burden of Substandard and Falsified Medicines in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis. JAMA Netw Open. 2018;1(4):e181662. doi: 10.1001/jamanetworkopen.2018.1662.

Sifuentes WQ, Guerrero JIA. La resistencia antimicrobiana en Perú: un problema de salud pública. Alpha Centauri. 2021;2(3):15–22. doi: 10.47422/ac.v2i3.38.

World Health Organization. Global surveillance and monitoring system for substandard and falsified medical products: activity report, August 2017–December 2021 [Internet]. Geneva: WHO; 2022 [cited 2026 mar 3]. Disponible en: https://iris.who.int/server/api/core/bitstreams/a4345304-1c22-4d19-bc79-57577428cbdc/content.

Pari Olarte JB, Loyola Gonzales E, Chávez Espinoza JH, Ambia Pereyra DE, Tataje Napuri FE, Kong Chirinos JF, et al. El uso de antibióticos y la amenaza de resistencia microbiana. Salud(i)Ciencia. 2025;27(5–6):235–48. doi: 10.21840/siic/175657.

Quino W, Bellido G, Flores-León D, Caro-Castro J, Mestanza O, Lucero J, et al. Trends in antimicrobial resistance of Shigella species in Peru, 2011–2020. JAC Antimicrob Resist. 2023;5(5):dlad110. doi:10.1093/jacamr/dlad110.

Sandoval KD, Deza-Santos F, Pinedo-Castillo L, Mateo-Pacora J, Rondan PL, Alcedo S, et al. Producción científica peruana sobre resistencia a los antimicrobianos de bacterias priorizadas por la OMS. Rev Cubana Med Trop. 2023;75(1). Disponible en: https://revmedtropical.sld.cu/index.php/medtropical/article/view/985.

Achong-Sánchez J, Lazo-Paredes R, Amado-Tineo J. Perfil microbiológico de sensibilidad y resistencia antimicrobiana en un hospital general de la selva peruana 2021. Rev Fac Med Hum. 2024;24(4):35–42. doi: 10.25176/rfmh.v24i4.6573.

Mayta-Barrios MM, Ramirez-Illescas JJ, Pampa-Espinoza L, Yagui-Moscoso MJA. Caracterización molecular de carbapenemasas en el Perú durante el 2019. Rev Peru Med Exp Salud Publica. 2021;38(1):113-118. doi: 10.17843/rpmesp.2021.381.5882.

Marcos-Carbajal P, Salvatierra G, Yareta J, Pino J, Vásquez N, Diaz P, et al. Caracterización microbiológica y molecular de la resistencia

antimicrobiana en Escherichia coli uropatógena de hospitales públicos peruanos. Rev Peru Med Exp Salud Publica. 2021;38(1):119–23. doi: 10.17843/rpmesp.2021.381.6182.

Soto Cabezas MG, Munayco Escate CV, Escalante Maldonado O, Valencia Torres E, Arica Gutiérrez J, Yagui Moscoso MJA. Perfil epidemiológico de la tuberculosis extensivamente resistente en el Perú, 2013–2015. Rev Panam Salud Publica. 2020;44:e29. doi: 10.26633/RPSP.2020.29.

Jorge-Berrocal A, Mayta-Barrios M, Fiestas-Solórzano V. Resistencia antimicrobiana de Neisseria gonorrhoeae en Perú. Rev Peru Med Exp Salud Publica. 2018; 35:155–6. doi: 10.17843/rpmesp.2018.351.3552.